Compare · CING vs NVO
CING vs NVO
Side-by-side comparison of Cingulate Inc. (CING) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CING and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $227.95B, about 3820.3x CING ($59.7M).
- Over the past year, CING is down 8.3% and NVO is down 22.9% - CING leads by 14.5 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 4 for CING).
- Company
- Cingulate Inc.
- Novo Nordisk A/S
- Price
- $4.51+1.81%
- $50.38-2.12%
- Market cap
- $59.7M
- $227.95B
- 1M return
- -5.25%
- +15.63%
- 1Y return
- -8.33%
- -22.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 5
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CING
- SEC Form S-8 filed by Cingulate Inc.
- Cingulate Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by EVP and CSO Silva Raul R.
- Cingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
- Cingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
- Director Hargroves Thomas Jeffrey bought $490,271 worth of shares (97,276 units at $5.04) (SEC Form 4)
- New insider Hargroves Thomas Jeffrey claimed ownership of 192 shares (SEC Form 3)
- Cingulate Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S